ELVN Q4 2025 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$46,000

Operating Income

-$34M

Net Income

-$30M

EPS (Diluted)

$-0.45

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$476M

Total Liabilities

$17M

Stockholders' Equity

$460M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$46,000	$0	—
Operating Income	-$34M	-$27M	-27.5%
Net Income	-$30M	-$23M	-28.0%